Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME: 2'-FL in Pediatric and Young Adult IBD Patients
NCT03847467Phase 2Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Sep 2019
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 2'-fucosyllactose in inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis (UC), sponsored by Cincinnati Children's Hospital Medical Center. Started Sep 2019; status: completed.
02
Drugs
2'-fucosyllactose
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03847467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847467.